Physician profile
Raymond Davidson
NPI 1790981884
$5,993.10
in general payments reported to CMS, 2019-2025
13 companies · $1,092 in 2025
The $1,092 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $436 · 2021: $766 · 2022: $332 · 2023: $774 · 2024: $1,990 · 2025: $1,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,796 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,796.49 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,699.86 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $1,443.52 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $678.67 | 2022-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $612.29 | 2019-2021 | |
| Indivior INC. | $586.09 | 2022-2024 | Perseris |
| Alkermes, INC. | $274.11 | 2019-2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $258.94 | 2020-2025 | Abilify Asimtufii, Abilify Maintena |
| Allergan, INC. | $145.03 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $108.97 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Avanir Pharmaceuticals, INC. | $101.70 | 2019 | |
| Neuronetics, INC. | $36.72 | 2023 | Neurostar Tms Therapy System |
| Takeda Pharmaceuticals U.S.A., INC. | $33.18 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.02 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.